Randomized phase 2 study of low-dose decitabine vs low-dose azacitidine in lower-risk MDS and MDS/MPN

Elias Jabbour, Nicholas J. Short, Guillermo Montalban-Bravo, Xuelin Huang, Carlos Bueso-Ramos, Wei Qiao, Hui Yang, Chong Zhao, Tapan Kadia, Gautam Borthakur, Naveen Pemmaraju, Koji Sasaki, Zeev Estrov, Jorge Cortes, Farhad Ravandi, Yesid Alvarado, Rami Komrokji, Mikkael A. Sekeres, David P. Steensma, Amy DezernGail Roboz, Hagop Kantarjian, Guillermo Garcia-Manero

Research output: Contribution to journalArticle

Abstract

Hypomethylating agents (HMAs) improve survival in patients with higher-risk myelodysplastic syndromes (MDS) but are less well-studied in lower-risk disease. We compared the safety and efficacy of low-dose decitabine vs low-dose azacitidine in this group of patients. Adults with low- or intermediate 1-risk MDS or MDS/myeloproliferative neoplasm (MPN), including chronic myelomonocytic leukemia, according to the International Prognostic Scoring System, were randomly assigned using a Bayesian adaptive design to receive either azacitidine 75 mg/m2 intravenously/subcutaneously daily or decitabine 20 mg/m2 intravenously daily for 3 consecutive days on a 28-day cycle. The primary outcome was overall response rate (ORR). Between November 2012 and February 2016, 113 patients were treated: 40 (35%) with azacitidine and 73 (65%) with decitabine. The median age was 70 years; 81% of patients were intermediate 1-risk patients. The median number of cycles received was 9. The ORRs were 70% and 49% (P 5 .03) for patients treated with decitabine and azacitidine, respectively. Thirty-two percent of patients treated with decitabine became transfusion independent compared with 16% of patients treated with azacitidine (P 5 .2). Cytogenetic response rates were 61% and 25% (P 5 .02), respectively. With a median follow-up of 20 months, the overall median event-free survival was 18 months: 20 and 13 months for patients treated with decitabine and azacitidine, respectively (P 5 .1). Treatment was well tolerated, with a 6-week mortality rate of 0%. The use of low-dose HMAs is safe and effective in patients with lower-risk MDS and MDS/MPN. Their effect on the natural history of lower-risk disease needs to be further studied. This trial was registered at clinicaltrials.gov (identifier NCT01720225).

Original languageEnglish (US)
Pages (from-to)1514-1522
Number of pages9
JournalBlood
Volume130
Issue number13
DOIs
StatePublished - Sep 28 2017

Fingerprint

decitabine
Azacitidine
Myelodysplastic Syndromes
Neoplasms
Leukemia, Myelomonocytic, Chronic

ASJC Scopus subject areas

  • Immunology
  • Biochemistry
  • Hematology
  • Cell Biology

Cite this

Jabbour, E., Short, N. J., Montalban-Bravo, G., Huang, X., Bueso-Ramos, C., Qiao, W., ... Garcia-Manero, G. (2017). Randomized phase 2 study of low-dose decitabine vs low-dose azacitidine in lower-risk MDS and MDS/MPN. Blood, 130(13), 1514-1522. https://doi.org/10.1182/blood-2017-06-788497

Randomized phase 2 study of low-dose decitabine vs low-dose azacitidine in lower-risk MDS and MDS/MPN. / Jabbour, Elias; Short, Nicholas J.; Montalban-Bravo, Guillermo; Huang, Xuelin; Bueso-Ramos, Carlos; Qiao, Wei; Yang, Hui; Zhao, Chong; Kadia, Tapan; Borthakur, Gautam; Pemmaraju, Naveen; Sasaki, Koji; Estrov, Zeev; Cortes, Jorge; Ravandi, Farhad; Alvarado, Yesid; Komrokji, Rami; Sekeres, Mikkael A.; Steensma, David P.; Dezern, Amy; Roboz, Gail; Kantarjian, Hagop; Garcia-Manero, Guillermo.

In: Blood, Vol. 130, No. 13, 28.09.2017, p. 1514-1522.

Research output: Contribution to journalArticle

Jabbour, E, Short, NJ, Montalban-Bravo, G, Huang, X, Bueso-Ramos, C, Qiao, W, Yang, H, Zhao, C, Kadia, T, Borthakur, G, Pemmaraju, N, Sasaki, K, Estrov, Z, Cortes, J, Ravandi, F, Alvarado, Y, Komrokji, R, Sekeres, MA, Steensma, DP, Dezern, A, Roboz, G, Kantarjian, H & Garcia-Manero, G 2017, 'Randomized phase 2 study of low-dose decitabine vs low-dose azacitidine in lower-risk MDS and MDS/MPN', Blood, vol. 130, no. 13, pp. 1514-1522. https://doi.org/10.1182/blood-2017-06-788497
Jabbour E, Short NJ, Montalban-Bravo G, Huang X, Bueso-Ramos C, Qiao W et al. Randomized phase 2 study of low-dose decitabine vs low-dose azacitidine in lower-risk MDS and MDS/MPN. Blood. 2017 Sep 28;130(13):1514-1522. https://doi.org/10.1182/blood-2017-06-788497
Jabbour, Elias ; Short, Nicholas J. ; Montalban-Bravo, Guillermo ; Huang, Xuelin ; Bueso-Ramos, Carlos ; Qiao, Wei ; Yang, Hui ; Zhao, Chong ; Kadia, Tapan ; Borthakur, Gautam ; Pemmaraju, Naveen ; Sasaki, Koji ; Estrov, Zeev ; Cortes, Jorge ; Ravandi, Farhad ; Alvarado, Yesid ; Komrokji, Rami ; Sekeres, Mikkael A. ; Steensma, David P. ; Dezern, Amy ; Roboz, Gail ; Kantarjian, Hagop ; Garcia-Manero, Guillermo. / Randomized phase 2 study of low-dose decitabine vs low-dose azacitidine in lower-risk MDS and MDS/MPN. In: Blood. 2017 ; Vol. 130, No. 13. pp. 1514-1522.
@article{618f8315d57249a2ae14a90cdce74658,
title = "Randomized phase 2 study of low-dose decitabine vs low-dose azacitidine in lower-risk MDS and MDS/MPN",
abstract = "Hypomethylating agents (HMAs) improve survival in patients with higher-risk myelodysplastic syndromes (MDS) but are less well-studied in lower-risk disease. We compared the safety and efficacy of low-dose decitabine vs low-dose azacitidine in this group of patients. Adults with low- or intermediate 1-risk MDS or MDS/myeloproliferative neoplasm (MPN), including chronic myelomonocytic leukemia, according to the International Prognostic Scoring System, were randomly assigned using a Bayesian adaptive design to receive either azacitidine 75 mg/m2 intravenously/subcutaneously daily or decitabine 20 mg/m2 intravenously daily for 3 consecutive days on a 28-day cycle. The primary outcome was overall response rate (ORR). Between November 2012 and February 2016, 113 patients were treated: 40 (35{\%}) with azacitidine and 73 (65{\%}) with decitabine. The median age was 70 years; 81{\%} of patients were intermediate 1-risk patients. The median number of cycles received was 9. The ORRs were 70{\%} and 49{\%} (P 5 .03) for patients treated with decitabine and azacitidine, respectively. Thirty-two percent of patients treated with decitabine became transfusion independent compared with 16{\%} of patients treated with azacitidine (P 5 .2). Cytogenetic response rates were 61{\%} and 25{\%} (P 5 .02), respectively. With a median follow-up of 20 months, the overall median event-free survival was 18 months: 20 and 13 months for patients treated with decitabine and azacitidine, respectively (P 5 .1). Treatment was well tolerated, with a 6-week mortality rate of 0{\%}. The use of low-dose HMAs is safe and effective in patients with lower-risk MDS and MDS/MPN. Their effect on the natural history of lower-risk disease needs to be further studied. This trial was registered at clinicaltrials.gov (identifier NCT01720225).",
author = "Elias Jabbour and Short, {Nicholas J.} and Guillermo Montalban-Bravo and Xuelin Huang and Carlos Bueso-Ramos and Wei Qiao and Hui Yang and Chong Zhao and Tapan Kadia and Gautam Borthakur and Naveen Pemmaraju and Koji Sasaki and Zeev Estrov and Jorge Cortes and Farhad Ravandi and Yesid Alvarado and Rami Komrokji and Sekeres, {Mikkael A.} and Steensma, {David P.} and Amy Dezern and Gail Roboz and Hagop Kantarjian and Guillermo Garcia-Manero",
year = "2017",
month = "9",
day = "28",
doi = "10.1182/blood-2017-06-788497",
language = "English (US)",
volume = "130",
pages = "1514--1522",
journal = "Blood",
issn = "0006-4971",
publisher = "American Society of Hematology",
number = "13",

}

TY - JOUR

T1 - Randomized phase 2 study of low-dose decitabine vs low-dose azacitidine in lower-risk MDS and MDS/MPN

AU - Jabbour, Elias

AU - Short, Nicholas J.

AU - Montalban-Bravo, Guillermo

AU - Huang, Xuelin

AU - Bueso-Ramos, Carlos

AU - Qiao, Wei

AU - Yang, Hui

AU - Zhao, Chong

AU - Kadia, Tapan

AU - Borthakur, Gautam

AU - Pemmaraju, Naveen

AU - Sasaki, Koji

AU - Estrov, Zeev

AU - Cortes, Jorge

AU - Ravandi, Farhad

AU - Alvarado, Yesid

AU - Komrokji, Rami

AU - Sekeres, Mikkael A.

AU - Steensma, David P.

AU - Dezern, Amy

AU - Roboz, Gail

AU - Kantarjian, Hagop

AU - Garcia-Manero, Guillermo

PY - 2017/9/28

Y1 - 2017/9/28

N2 - Hypomethylating agents (HMAs) improve survival in patients with higher-risk myelodysplastic syndromes (MDS) but are less well-studied in lower-risk disease. We compared the safety and efficacy of low-dose decitabine vs low-dose azacitidine in this group of patients. Adults with low- or intermediate 1-risk MDS or MDS/myeloproliferative neoplasm (MPN), including chronic myelomonocytic leukemia, according to the International Prognostic Scoring System, were randomly assigned using a Bayesian adaptive design to receive either azacitidine 75 mg/m2 intravenously/subcutaneously daily or decitabine 20 mg/m2 intravenously daily for 3 consecutive days on a 28-day cycle. The primary outcome was overall response rate (ORR). Between November 2012 and February 2016, 113 patients were treated: 40 (35%) with azacitidine and 73 (65%) with decitabine. The median age was 70 years; 81% of patients were intermediate 1-risk patients. The median number of cycles received was 9. The ORRs were 70% and 49% (P 5 .03) for patients treated with decitabine and azacitidine, respectively. Thirty-two percent of patients treated with decitabine became transfusion independent compared with 16% of patients treated with azacitidine (P 5 .2). Cytogenetic response rates were 61% and 25% (P 5 .02), respectively. With a median follow-up of 20 months, the overall median event-free survival was 18 months: 20 and 13 months for patients treated with decitabine and azacitidine, respectively (P 5 .1). Treatment was well tolerated, with a 6-week mortality rate of 0%. The use of low-dose HMAs is safe and effective in patients with lower-risk MDS and MDS/MPN. Their effect on the natural history of lower-risk disease needs to be further studied. This trial was registered at clinicaltrials.gov (identifier NCT01720225).

AB - Hypomethylating agents (HMAs) improve survival in patients with higher-risk myelodysplastic syndromes (MDS) but are less well-studied in lower-risk disease. We compared the safety and efficacy of low-dose decitabine vs low-dose azacitidine in this group of patients. Adults with low- or intermediate 1-risk MDS or MDS/myeloproliferative neoplasm (MPN), including chronic myelomonocytic leukemia, according to the International Prognostic Scoring System, were randomly assigned using a Bayesian adaptive design to receive either azacitidine 75 mg/m2 intravenously/subcutaneously daily or decitabine 20 mg/m2 intravenously daily for 3 consecutive days on a 28-day cycle. The primary outcome was overall response rate (ORR). Between November 2012 and February 2016, 113 patients were treated: 40 (35%) with azacitidine and 73 (65%) with decitabine. The median age was 70 years; 81% of patients were intermediate 1-risk patients. The median number of cycles received was 9. The ORRs were 70% and 49% (P 5 .03) for patients treated with decitabine and azacitidine, respectively. Thirty-two percent of patients treated with decitabine became transfusion independent compared with 16% of patients treated with azacitidine (P 5 .2). Cytogenetic response rates were 61% and 25% (P 5 .02), respectively. With a median follow-up of 20 months, the overall median event-free survival was 18 months: 20 and 13 months for patients treated with decitabine and azacitidine, respectively (P 5 .1). Treatment was well tolerated, with a 6-week mortality rate of 0%. The use of low-dose HMAs is safe and effective in patients with lower-risk MDS and MDS/MPN. Their effect on the natural history of lower-risk disease needs to be further studied. This trial was registered at clinicaltrials.gov (identifier NCT01720225).

UR - http://www.scopus.com/inward/record.url?scp=85030033047&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85030033047&partnerID=8YFLogxK

U2 - 10.1182/blood-2017-06-788497

DO - 10.1182/blood-2017-06-788497

M3 - Article

C2 - 28774880

AN - SCOPUS:85030033047

VL - 130

SP - 1514

EP - 1522

JO - Blood

JF - Blood

SN - 0006-4971

IS - 13

ER -